Intersect ENT (XENT) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
- Bernstein on Crypto: 'Clarity fails - what next?'
Leerink Partners Cuts Price Target on Intersect ENT (XENT) to $14; Reiterates Outperform
November 3, 2016 7:41 AM EDTLeerink Partners maintained an Outperform rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $14.00 (from $21.00), following the company's 3Q and sell-off. Revenues of $18.5M beat consensus $17.8M and reflected a second consecutive quarter of y/y sales growth acceleration.
Analyst Richard Newitter commented, "Following XENT's massive... More
